Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Trading Statement

3 Oct 2011 07:00

RNS Number : 3414P
Tarsus Group PLC
03 October 2011
 



Tarsus Group plc

3 October 2011

Disposal of French Joint Venture

and

Trading Update

Modamont - France

 

Tarsus Group plc ('Tarsus', the 'Group' or the 'Company'), the international business-to-business media group, is pleased to announce that it has reached agreement to dispose of its 51 per cent. interest in the joint venture, Modamont SAS ("Modamont"), to its joint venture partner, Premiere Vision SAS, for a total consideration of €6.1 million (the "Disposal").

 

Modamont is the leading exhibition for fashion accessories in France and takes place bi-annually in Paris in February and September. In the year ended 31 December 2010 Tarsus's 51 per cent. share of Modamont revenues and profits were approximately €2.2 million and €0.6 million respectively. Tarsus's share of Modamont's net assets were approximately €0.7 million as at 30 September 2011. Tarsus's share of Modamont's gross assets as at 30 June 2011 were approximately €1.5 million. At completion, Tarsus France SAS will repay a loan of €2.2 million to Modamont. The net proceeds from the Disposal will be used to give additional flexibility to the Company's balance sheet.

 

Owing to its significant shareholding in Modamont, Premiere Vision is considered to be a related party for the purposes of the Listing Rules and the Disposal therefore constitutes a related party transaction. Consequently, the Disposal is subject to and conditional upon the approval of shareholders in the Company at a general meeting. Further details of the Disposal and a notice convening a general meeting to approve the Disposal will be sent to Tarsus shareholders in due course.

 

Trading Update

 

Since the announcement of the Group's interim results on 27 July 2011, the Group has held three major exhibitions. Off Price took place in Las Vegas in August 2011 and generated a like-for-like revenue increase of approximately 6 per cent. Modamont and Labelexpo Europe (the second largest show in the Group's portfolio, held in Brussels) both took place in September and produced like-for-like revenue increases of 9 per cent. and over 10 per cent. respectively, both slightly ahead of management's expectations. The Group's largest event in the fourth quarter, the Dubai Airshow, is on track to meet management's expectations.

 

Forward bookings continue to be strong and the Board is increasingly confident of good progress being made this year.

 

Douglas Emslie, Group Managing Director of Tarsus, commented:

 

"The disposal of Modamont will materially reduce our exposure to the lower growth European market and less than 10 per cent. of Group profits will now be generated from France. Tarsus France will continue to focus on its remaining wholly owned portfolio of exhibitions.

 

We now have greater financial flexibility to accelerate our drive into the faster growth emerging markets where we are actively pursuing potential acquisitions. As we continue to execute our growth strategy we anticipate a further significant increase in the proportion of our business coming from the emerging markets".

 

For further information, please contact:

 

Tarsus Group plc:

 

Douglas Emslie, Group Managing Director 020 8846 2700

Dan O'Brien, Group Finance Director 020 8846 2700

 

Media

Madano Partnership:

Matthew Moth 020 7593 4000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUROSRAVAKOAR
Date   Source Headline
16th May 20197:00 amRNSTrading Update
9th May 20196:19 pmRNSBlock Listing Six Monthly Return
30th Apr 201910:14 amRNSTotal Voting Rights
16th Apr 20192:40 pmRNSDirector/PDMR Shareholding
2nd Apr 20193:43 pmRNSBlock listing Interim Review
1st Apr 201910:44 amRNSTotal Voting Rights
19th Mar 201911:42 amRNS2018 Annual Report
8th Mar 20194:36 pmRNSPrice Monitoring Extension
27th Feb 20197:00 amRNSFinal Results
6th Feb 20194:35 pmRNSPrice Monitoring Extension
31st Jan 201911:53 amRNSTotal Voting Rights
30th Jan 20197:00 amRNSOption agreement re Tarsus Connect
16th Jan 20194:22 pmRNSApplication for Admission
14th Jan 20197:00 amRNSYear-end Trading Update
13th Dec 20184:48 pmRNSScrip Dividend Circular (the "Circular")
30th Nov 20183:10 pmRNSTotal Voting Rights
20th Nov 20181:44 pmRNSApplication for Admission
6th Nov 20187:00 amRNSCapital Markets Seminar and Trading Update
1st Nov 20182:56 pmRNSTotal Voting Rights
18th Sep 20186:20 pmRNSDirector/PDMR Shareholding
14th Sep 201812:06 pmRNSResults of Placing
14th Sep 20187:00 amRNSAcquisitions and Placing of New Ordinary Shares
10th Sep 20183:18 pmRNSBlock Listing Six Monthly Return
31st Aug 20183:39 pmRNSTotal Voting Rights
24th Aug 201811:17 amRNSHalf-year Report
1st Aug 201811:54 amRNSTotal Voting Rights
26th Jul 20187:00 amRNSHalf-year Report
13th Jul 20182:34 pmRNSApplication for Admission - scrip dividend shares
13th Jul 20182:18 pmRNSDirector Declaration
21st Jun 20181:52 pmRNSResult of AGM
18th Jun 20183:37 pmRNSHolding(s) in Company
12th Jun 20184:41 pmRNSDirector/PDMR Shareholding
8th Jun 20183:45 pmRNSScrip Dividend Circular
1st Jun 201812:31 pmRNSTotal Voting Rights
21st May 20186:10 pmRNSNotice of AGM
17th May 20187:00 amRNSTrading Update
9th May 20187:00 amRNSBoard Changes
9th May 20187:00 amRNSBlock Listing Six Monthly Return
1st May 201811:45 amRNSTotal Voting Rights and Capital
20th Apr 201812:15 pmRNSDirector/PDMR Shareholding
20th Apr 201812:14 pmRNSDirector/PDMR Shareholding
18th Apr 20184:29 pmRNSNotification of Transactions
29th Mar 201810:50 amRNSTotal Voting Rights
22nd Mar 20185:01 pmRNS2017 Annual Report
9th Mar 20183:54 pmRNSDirector/PDMR Shareholding
6th Mar 201810:18 amRNSBlock Listing Six Monthly Return
5th Mar 20185:06 pmRNSDirector/PDMR Shareholding
28th Feb 20187:00 amRNSFinal Results
31st Jan 20189:40 amRNSTotal Voting Rights
12th Jan 201810:30 amRNSApplication for Admission - scrip dividend shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.